Abstract: A method for treating exposure of surgical mesh in a subject generally includes administering PEP to tissue adjacent to an area of exposed surgical mesh in an amount effective to treat the area of exposed surgical mesh. In another aspect, a method for treating exposure of surgical mesh in a subject generally includes surgically closing an area of exposed surgical mesh and administering PEP to epithelium adjacent to the surgical closure in an amount effective to treat the area of exposed surgical mesh. In one or more embodiments of either aspect, the amount effective to treat the area of exposed surgical mesh can be an amount effective to increase proliferation of epithelium to decrease the area of exposed surgical mesh, increase thickness of epithelium covering the surgical mesh, or increase vascularization of epithelium covering the surgical mesh.

Abstract: A method of treating injured skeletal muscle tissue generally includes applying to injured skeletal muscle tissue a therapeutic composition that includes a purified exosome product (PEP) and a pharmaceutically acceptable carrier. In one or more embodiments, the method includes applying from 1×1011 PEP exosomes to 1×1013 PEP exosomes to the injured skeletal muscle. In one or more embodiments, the therapeutic composition further includes a supportive matrix such as a collagen scaffold, a tissue sealant, fibrin glue, or a hydrogel.

Abstract: Devices and methods are described for injecting therapeutics into tissue. For example, some embodiments disclosed in this document describe devices and methods for injecting muscle precursor cells into the sphincter urethrae to treat stress urinary incontinence.